Overview

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Status:
Completed
Trial end date:
2017-11-23
Target enrollment:
Participant gender:
Summary
This purpose of this study is to evaluate the effects of a single dose of entinostat on subjects with varying levels of renal impairment. The primary objective of this study is to evaluate the pharmacokinetics of a single dose of entinostat in adult subjects with mild, moderate and severe renal impairment compared to healthy mean-matched subjects. The secondary objective of this study is to evaluate the safety and tolerability of entinostat in adult subjects with mild, moderate, and severe renal impairment and in healthy mean-matched adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Syndax Pharmaceuticals
Treatments:
Entinostat
Histone Deacetylase Inhibitors